TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7093924

Group type: EXPERIMENTAL
Intervention: Polychemotherapy (MACC: methotrexate, doxorubicine hydrochloride, cyclophosphamide, and lomustine)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Polychemotherapy (MACC)
Number of subjects: 39
Study: 31573911

Group type: EXPERIMENTAL
Intervention: Mode-tailored website (textual, visual, audiovisual modes)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Nontailored website (text only, text with images, text with videos)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Mode-tailored website
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Knowledge before consultation (T1)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Time on the website (T1)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Knowledge from the website afterward (T3)
Number of subjects: 232
Study: 30071821

Group type: EXPERIMENTAL
Intervention: Victoria intervention (three half‐day training sessions and bi‐monthly supervision meetings for 18 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 26891418

Group type: EXPERIMENTAL
Intervention: Ledipasvir/Sofosbuvir and ribavirin for 12 or 24 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline factors associated with HCV RNA <LLOQ at week 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline factors associated with HCV RNA <LLOQ at week 4
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early on-treatment HCV RNA
Number of subjects: 0
Study: 24950920

Group type: EXPERIMENTAL
Intervention: Low tidal volume with PEEP (tidal volume = 6 mL/kg, rate = 18/minute, PEEP = 5 cm H(2)O)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional group (tidal volume = 10 mL/kg, rate = 12/minute, PEEP = 0 cm H(2)O)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (low tidal and conventional)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low tidal group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 21598243

Group type: EXPERIMENTAL
Intervention: Combination of ixabepilone and capecitabine (once every 21 days)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Capecitabine alone (on days 1-14)
Number of subjects: 752
Study: 19174497

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17991646

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: HFCS 55 (G45:F55)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: G20:F80
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: G35:F65
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: G50:F50
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: G80:F20
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-glucose solutions
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Low-glucose solutions
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Insulin and BG AUCs
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sweet energy-free control (experiment 1)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Water (both experiments)
Number of subjects: 31
Study: 15342619

Group type: EXPERIMENTAL
Intervention: Intramuscular haloperidol (7.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intramuscular lorazepam (4 mg)
Number of subjects: 12
Study: 11334193

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-heparin-bonded circuits
Number of subjects: 39
Study: 9587048

Group type: EXPERIMENTAL
Intervention: benfotiamin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: fursultiamin
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: thiaminedisulfide
Number of subjects: 7
Study: 8017465

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg with the evening meal
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg at bedtime
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo at mealtime and at bedtime
Number of subjects: 44
Study: 2574115

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terfenadine 60 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Terfenadine 120 mg
Number of subjects: 10
Study: 1277740

Group type: EXPERIMENTAL
Intervention: Infusion of methylglucamine iodipamide
Number of subjects: 50

Group type: COMPARATOR
Intervention: Single bolus injection of methylglucamine iodipamide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both methods (infusion and single bolus)
Number of subjects: 50
Study: 31260843

Group type: EXPERIMENTAL
Intervention: Single‐Bundle‐Lateral‐Plasty (SBLP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Single Bundle (SB)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Double Bundle (DB)
Number of subjects: 42
Study: 28600833

Group type: EXPERIMENTAL
Intervention: Mobile app (App, n=42)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wearable Bite Counter device (Bite, n=39)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Mobile app (App)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wearable Bite Counter device (Bite)
Number of subjects: 81
Study: 25636814

Group type: EXPERIMENTAL
Intervention: WBVT + L-citrulline
Number of subjects: 41

Group type: COMPARATOR
Intervention: All interventions (WBVT, L-citrulline, WBVT + L-citrulline)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both WBVT interventions (WBVT and WBVT + L-citrulline)
Number of subjects: 41
Study: 23065090

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg daily for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Rabeprazole 20 mg daily for 4 weeks
Number of subjects: 70
Study: 22035999

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment
Number of subjects: 78
Study: 18829112

Group type: EXPERIMENTAL
Intervention: Average team member Openness to Experience
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Average team member Conscientiousness
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Average team member Agreeableness
Number of subjects: 159
Study: 16835031

Group type: EXPERIMENTAL
Intervention: Massage therapy (gentle rubbing, stroking, passive movements of the limbs) performed by professionals until the infant is 8 months old
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (healthy LBW infants)
Number of subjects: 50
Study: 15577227

Group type: EXPERIMENTAL
Intervention: Ninjin-to (6.0 g, single oral administration)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 11387994

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NIF patients
Number of subjects: 0
Study: 9247407

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (24‐hour low‐tryptophan diet and ingestion of a tryptophan‐free amino acid beverage)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control testing (diet and beverage supplemented with tryptophan)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control testing
Number of subjects: 11
Study: 8286514

Group type: EXPERIMENTAL
Intervention: One day course of ampicillin and metronidazole
Number of subjects: 88

Group type: COMPARATOR
Intervention: Four day course of ampicillin and metronidazole
Number of subjects: 88
Study: 3087617

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) at 60 mg/m2, Ifosfamide (IFF) at 7500 mg/m2, Dacarbazine (DTIC) at 900 mg/m2 by continuous infusion over 72 hours
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) by continuous infusion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX), Ifosfamide (IFF), Dacarbazine (DTIC)
Number of subjects: 20
Study: 31943737

Group type: EXPERIMENTAL
Intervention: Treatment assignment with a biomarker measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time-dependent logistic model for treatment response
Number of subjects: 0
Study: 29546305

Group type: EXPERIMENTAL
Intervention: Daily nutritional dose of antioxidant supplement (120 mg vitamin C, 6 mg β-carotene, 30 mg vitamin E, 100 μg Se, 20 mg Zn)
Number of subjects: 2796

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2796
Study: 28209452

Group type: EXPERIMENTAL
Intervention: 5 moments for patient hand hygiene educational intervention
Number of subjects: 0
Study: 26698262

Group type: EXPERIMENTAL
Intervention: 180 mg ticagrelor
Number of subjects: 74

Group type: COMPARATOR
Intervention: 600 mg clopidogrel
Number of subjects: 74
Study: 24040848

Group type: EXPERIMENTAL
Intervention: Ospemifene with high-fat breakfast (860 kcal)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ospemifene with low-fat breakfast (300 kcal)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ospemifene without food (overnight fast)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dissolution in fed intestinal fluid
Number of subjects: 24
Study: 21438929

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Baseline CSF L‐PGDS
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Change of CSF L‐PGDS after weight loss
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Serum L‐PGDS
Number of subjects: 26
Study: 17967218

Group type: EXPERIMENTAL
Intervention: Aquacultured salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wild salmon (250 g daily for 4 weeks providing 5 mug AST/g salmon flesh)
Number of subjects: 28
Study: 16832316

Group type: EXPERIMENTAL
Intervention: Stimulant medication
Number of subjects: 1610
Study: 15319047

Group type: EXPERIMENTAL
Intervention: Home telehealth intervention
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual home healthcare services (Control)
Number of subjects: 104
Study: 11467624

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) over 4 weeks
Number of subjects: 1143
Study: 9015888

Group type: EXPERIMENTAL
Intervention: Tibetan treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Western treatment
Number of subjects: 0
Study: 8243825

Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia (2.5 mM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia with combined α‐ and β‐ adrenergic blockade (phentolamine and propranolol)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clamped hypoglycemia with panautonomic blockade (phentolamine, propranolol and atropine)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Clamped euglycemia (5 mM)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neurogenic symptoms (adrenergic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neurogenic symptoms (cholinergic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neuroglycopenic symptoms
Number of subjects: 10
Study: 2945704

Group type: EXPERIMENTAL
Intervention: 1 percent clindamycin phosphate lotion
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 28948645

Group type: EXPERIMENTAL
Intervention: Doxycycline hyclate (50 mg/d)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 27909120

Group type: EXPERIMENTAL
Intervention: Peripheral reaming technique
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard reaming technique
Number of subjects: 0
Study: 24351079

Group type: EXPERIMENTAL
Intervention: OC/APAP ER
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study: 23098480

Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Knowledge about cervical cancer and HPV vaccine
Number of subjects: 612

Group type: EXPERIMENTAL
Intervention: Factors influencing HPV vaccine uptake
Number of subjects: 612
Study: 20335115

Group type: EXPERIMENTAL
Intervention: PGEl + ACEI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PGEl
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal treatment (Control group)
Number of subjects: 0
Study: 18752509

Group type: EXPERIMENTAL
Intervention: Preserved tafluprost 0.0015% eyedrops
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preservative-free tafluprost 0.0015% eyedrops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 0
Study: 11380317

Group type: EXPERIMENTAL
Intervention: Rabeprazole (10 mg or 20 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Water only (baseline data)
Number of subjects: 18
Study: 9691892

Group type: EXPERIMENTAL
Intervention: Fast Spin Echo Proton Density (FSE PD)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Spin Echo T1 (SE T1)
Number of subjects: 116
Study: 7938668

Group type: EXPERIMENTAL
Intervention: Unfamiliar and/or distinctive cues
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-minutes' delay between instructions and task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceptual distinctiveness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filled delay with demanding interpolated activity (practice in a STM task)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filled delay with undemanding motoric activity (repetitive hands movements)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfilled delay with undemanding verbal activity (counting)
Number of subjects: 0
Study: 2851179

Group type: COMPARATOR
Intervention: Etoposide (single-agent)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Cisplatin and etoposide (VP-16)
Number of subjects: 216
Study: 31333199

Group type: EXPERIMENTAL
Intervention: Link intervention (Web-based mental health help-seeking navigation tool)
Number of subjects: 413
Study: 28495410

Group type: EXPERIMENTAL
Intervention: Immediate reconstruction of the inferior alveolar nerve with a long processed nerve allograft (PNA) longer than 4.5 cm.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Positive control (no nerve repair).
Number of subjects: 26
Study: 26817211

Group type: EXPERIMENTAL
Intervention: Feeding tube
Number of subjects: 120

Group type: COMPARATOR
Intervention: Cup feeding
Number of subjects: 120
Study: 23123199

Group type: EXPERIMENTAL
Intervention: Aerobic walking group
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-aerobic control group
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pre-intervention VEGF levels
Number of subjects: 65
Study: 21245953

Group type: EXPERIMENTAL
Intervention: C-T haplotype established by rs3793342 and rs11771443
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 190
Study: 18307592

Group type: EXPERIMENTAL
Intervention: RBV plus 1.5 microg/kg/week Peg‐IFN‐alpha2b
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RBV plus 1.0 microg/kg/week Peg‐IFN‐alpha2b
Number of subjects: 45

Group type: COMPARATOR
Intervention: Early virological responders (EVR)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Rapid virological responders (RVR)
Number of subjects: 45
Study: 16965639

Group type: EXPERIMENTAL
Intervention: Behavioral addiction treatment with systematic reinforcement for goal attainment
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Behavioral addiction treatment
Number of subjects: 95
Study: 14633804

Group type: EXPERIMENTAL
Intervention: 1 g of cinnamon daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 g of cinnamon daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6 g of cinnamon daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10627108

Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Aftercare treatment
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Therapist ratings in outpatient sample
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Therapist ratings in aftercare sample
Number of subjects: 1187
Study: 9113223

Group type: EXPERIMENTAL
Intervention: Restart program for men
Number of subjects: 1004

Group type: COMPARATOR
Intervention: No Restart program for men
Number of subjects: 1004

Group type: EXPERIMENTAL
Intervention: Restart program for women
Number of subjects: 1004

Group type: COMPARATOR
Intervention: No Restart program for women
Number of subjects: 1004
Study: 1586358

Group type: EXPERIMENTAL
Intervention: Pure exposure
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interoceptive exposure
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Modification of negative cognitions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31847919

Group type: EXPERIMENTAL
Intervention: PEGASO system
Number of subjects: 525

Group type: COMPARATOR
Intervention: Usual educational routine
Number of subjects: 525
Study: 30227152

Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 42

Group type: COMPARATOR
Intervention: Mock-infiltration (control)
Number of subjects: 42
Study: 25452309

Group type: EXPERIMENTAL
Intervention: Diffusing capacity for carbon monoxide (DLCO)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Forced vital capacity (FVC)
Number of subjects: 300
Study: 24506950

Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioral therapy (CBT-T)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Nondirective supportive therapy (NST-T)
Number of subjects: 176
Study: 22640439

Group type: EXPERIMENTAL
Intervention: Decision aids (Statin Choice and Aspirin Choice, or Diabetes Medication Choice)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 20678673

Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/d
Number of subjects: 1467

Group type: COMPARATOR
Intervention: Donepezil 10 mg/d
Number of subjects: 1467
Study: 19055286

Group type: EXPERIMENTAL
Intervention: Massage for supplementing qi and removing obstruction in the Governor Vessel
Number of subjects: 275

Group type: COMPARATOR
Intervention: Routine massage therapy in Tuina Science (Control)
Number of subjects: 275
Study: 16649966

Group type: EXPERIMENTAL
Intervention: B vitamins (5 mg of folic acid and 250 mg of pyridoxine)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: B vitamins (5 mg of folic acid)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12839261

Group type: EXPERIMENTAL
Intervention: 0.01% estradiol cream
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: 15% glycolic acid cream
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Combination of 0.01% estradiol and 15% glycolic acid creams
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 65
Study: 10811761

Group type: EXPERIMENTAL
Intervention: Direct cooling of the injured hand
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Body tilt
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy contralateral digits (control)
Number of subjects: 10
Study: 8862047

Group type: EXPERIMENTAL
Intervention: Cytopathologic assessment of cell type
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard prognostic variables
Number of subjects: 116
Study: 1635124

Group type: EXPERIMENTAL
Intervention: Internal urethrotomy followed by clean intermittent self-catheterization for 3 months
Number of subjects: 61

Group type: COMPARATOR
Intervention: Internal urethrotomy only (observation group)
Number of subjects: 61
Study: 6720281

Group type: COMPARATOR
Intervention: Indomethacin solution (1% watery solution, 1 drop, 4 times a day for 2 weeks)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Indomethacin solution (local application during the first week post-surgery)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Routine treatment with antibiotics and corticosteroid (from the third post-operative day)
Number of subjects: 74
Study: 31582360

Group type: EXPERIMENTAL
Intervention: High-titre anti-influenza plasma (haemagglutination inhibition antibody titre ≥1:80)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-titre plasma (≤1:10)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-titre group
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-titre group
Number of subjects: 200
Study: 28811653

Group type: EXPERIMENTAL
Intervention: 50% of daily energy consumed in the morning (BF group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 50% of daily energy consumed in the evening (D group)
Number of subjects: 23
Study: 26742068

Group type: EXPERIMENTAL
Intervention: Normal protein (12 g) + normal fiber (2 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normal protein (12 g) + high fiber (8 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High protein (25 g) + normal fiber (2 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High protein (25 g) + high fiber (8 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normal protein (12 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High protein (25 g)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Visual food stimuli
Number of subjects: 15
Study: 24958250

Group type: EXPERIMENTAL
Intervention: Electronic cigarette (medium-strength nicotine concentration 11 mg/ml for 7 minutes)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Regular cigarette (1 cigarette)
Number of subjects: 76
Study: 22660375

Group type: EXPERIMENTAL
Intervention: Anodyne NIR device
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: HealthLight NIR device
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 15
Study: 20539854

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk management package including education about risk factors and treatment with hydrochlorothiazide at 4 months for medium-risk patients.
Number of subjects: 2397

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 2397
Study: 17448569

Group type: EXPERIMENTAL
Intervention: Low glycemic-load diet
Number of subjects: 43

Group type: COMPARATOR
Intervention: High glycemic-load diet
Number of subjects: 43
Study: 15732857

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40